This page shows the latest neratinib news and features for those working in and with pharma, biotech and healthcare.
There was worse news for Puma Biotechnology - which has its application to market Nerlyx (neratinib) for breast cancer turned down - and also Pfizer whose application to extend the indications of Sutent
The results of the APHINITY trial could present an opportunity to US biotech Puma, which won a positive recommendation from an FDA advisory committee for its neratinib candidate in post-surgery ... In trials, neratinib achieved a 33% reduction in the
US biotech Puma took a step closer to approval of its breast cancer therapy neratinib after an FDA advisory committee voted in favour of the drug. ... A number of analysts have suggested neratinib may be approved only in patients with hormone
Pfizer has licensed the worldwide commercial rights of Neratinib, a phase II pan-HER inhibitor (potent irreversible tyrosine kinase inhibitor) in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive ... 2 ##. Pfizer/Puma Biotechnology ##
I-SPY 2 has already brought together compounds from Pfizer (neratinib), Abbott Laboratories (ABT-888) and Takeda Pharmaceutical Industries (AMT-386), and there appears to be an almost unprecedented level of
HER2 inhibitor neratinib (Pfizer) and the PARP inhibitor veliparib (Abbott Laboratories).
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Anthill is a specialist digital agency and a strategic partner for life science companies....